Cumulative Incidence of Mortality Associated with Cardiovascular–Kidney–Metabolic (CKM) Syndrome
Journal of the American Society of Nephrology · 2025-07 · 36 (7) · 1343-1351
DOI: 10.1681/asn.0000000637 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 11.02.2025. Verfasst von Sophie E Claudel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Boston Medical Center, Boston, Massachusetts. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Key Points Cardiovascular–kidney–metabolic (CKM) syndrome stages 1–4 were associated with a graded risk of cardiovascular mortality in a nationally representative sample of US adults. Risk was similar between stages 0 and 1, suggesting that stage 1 represents a prime opportunity for prevention and risk mitigation. CKM staging is specific to cardiovascular mortality, given lack of a strong association with either noncardiovascular or cancer mortality.
Background
It is imperative to critically evaluate the prognostic implications of cardiovascular–kidney–metabolic (CKM) syndrome staging to inform clinical practice. The primary aims of this study were to define the risk of mortality associated with each CKM syndrome stage and to determine the corresponding restricted mean survival time over a 15-year period.
Methods
This was a longitudinal study of 50,678 community-dwelling US adults aged 20 years and older with baseline data for CKM stage determination participating in the 1999–2018 National Health and Nutrition Examination Survey. CKM stages were defined according to the American Heart Association presidential advisory. Fifteen-year adjusted cumulative incidences of cardiovascular mortality were calculated for each stage from confounder-adjusted survival curves using the G-formula.
Results
Over a median 9.5-year follow-up, 2564 participants experienced cardiovascular death. The 15-year adjusted cumulative incidences of cardiovascular mortality were stage 0, 5.5% (95% confidence interval [CI], 1.8 to 9.3); stage 1, 5.7% (95% CI, 3.2 to 8.2); stage 2, 7.9% (95% CI, 6.8 to 9.1); stage 3, 8.7% (95% CI, 6.7 to 10.8); and stage 4, 15.2% (95% CI, 13.6 to 16.8). The absolute risk difference between CKM stage 4 and stage 0 at 15 years was 9.6% (95% CI, 5.6 to 13.6). The survival difference between CKM stage 0 and stage 4 at 15 years was 8.1 (95% CI, 8.0 to 8.2) months.
Conclusions
Our findings reveal a graded risk of cardiovascular mortality associated with higher CKM syndrome stage.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Boston Medical Center, Boston, Massachusetts.
- Section of Nephrology, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.
ORCID-Profile: Sophie E Claudel, Insa M Schmidt, Ashish Verma
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Claudel, S. E., Schmidt, I. M., Waikar, S. S., & Verma, A. (2025). Cumulative Incidence of Mortality Associated with Cardiovascular–Kidney–Metabolic (CKM) Syndrome. Journal of the American Society of Nephrology, 36(7), 1343-1351. https://doi.org/10.1681/asn.0000000637
Vancouver
Claudel SE, Schmidt IM, Waikar SS, Verma A. Cumulative Incidence of Mortality Associated with Cardiovascular–Kidney–Metabolic (CKM) Syndrome. Journal of the American Society of Nephrology. 2025;36(7):1343-1351. doi:10.1681/asn.0000000637
BibTeX
@article{Claudel2025,
author = {Claudel, Sophie E and Schmidt, Insa M and Waikar, Sushrut S and Verma, Ashish},
title = {Cumulative Incidence of Mortality Associated with Cardiovascular–Kidney–Metabolic (CKM) Syndrome},
journal = {Journal of the American Society of Nephrology},
year = {2025},
volume = {36},
number = {7},
pages = {1343--1351},
doi = {10.1681/asn.0000000637}
}
EUVIMED